Handling oxygenation targets in ICU patients with COVID-19-Protocol and statistical analysis plan in the HOT-COVID trial.
COVID-19
hypoxia
intensive care units
oxygen
Journal
Acta anaesthesiologica Scandinavica
ISSN: 1399-6576
Titre abrégé: Acta Anaesthesiol Scand
Pays: England
ID NLM: 0370270
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
29
07
2021
received:
07
07
2021
accepted:
16
07
2021
pubmed:
27
7
2021
medline:
28
10
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Coronavirus disease (COVID-19) primarily affects the lungs and lower airways and may present as hypoxaemic respiratory failure requiring admission to an intensive care unit (ICU) for supportive treatment. Here, supplemental oxygen remains essential for COVID-19 patient management, but the optimal dosage is not defined. We hypothesize that targeting an arterial partial pressure of oxygen of 8 kPa throughout ICU admission is superior to targeting 12 kPa. The Handling Oxygenation Targets in ICU patients with COVID-19 (HOT-COVID) trial, is an investigator-initiated, pragmatic, multicentre, randomized, parallel-group trial comparing a lower oxygenation target versus a higher oxygenation target in adult ICU patients with COVID-19. The primary outcome is days alive without life-support (use of mechanical ventilation, renal replacement therapy or vasoactive therapy) at day 90. Secondary outcomes are 90-day and 1-year mortality, serious adverse events in the ICU and days alive and out of hospital in the 90-day period, health-related quality-of-life at 1 year, and health economic analyses. One-year follow-up of cognitive and pulmonary function is planned in a subgroup of Danish patients. We will include 780 patients to detect or reject an absolute increase in days alive without life-support of 7 days with an α of 5% and a β of 20%. An interim analysis is planned after 90-day follow-up of 390 patients. The HOT-COVID trial will provide patient-important data on the effect of two oxygenation targets in ICU patients with COVID-19 and hypoxia. This protocol paper describes the background, design and statistical analysis plan for the trial.
Sections du résumé
BACKGROUND
Coronavirus disease (COVID-19) primarily affects the lungs and lower airways and may present as hypoxaemic respiratory failure requiring admission to an intensive care unit (ICU) for supportive treatment. Here, supplemental oxygen remains essential for COVID-19 patient management, but the optimal dosage is not defined. We hypothesize that targeting an arterial partial pressure of oxygen of 8 kPa throughout ICU admission is superior to targeting 12 kPa.
METHODS
The Handling Oxygenation Targets in ICU patients with COVID-19 (HOT-COVID) trial, is an investigator-initiated, pragmatic, multicentre, randomized, parallel-group trial comparing a lower oxygenation target versus a higher oxygenation target in adult ICU patients with COVID-19. The primary outcome is days alive without life-support (use of mechanical ventilation, renal replacement therapy or vasoactive therapy) at day 90. Secondary outcomes are 90-day and 1-year mortality, serious adverse events in the ICU and days alive and out of hospital in the 90-day period, health-related quality-of-life at 1 year, and health economic analyses. One-year follow-up of cognitive and pulmonary function is planned in a subgroup of Danish patients. We will include 780 patients to detect or reject an absolute increase in days alive without life-support of 7 days with an α of 5% and a β of 20%. An interim analysis is planned after 90-day follow-up of 390 patients.
CONCLUSIONS
The HOT-COVID trial will provide patient-important data on the effect of two oxygenation targets in ICU patients with COVID-19 and hypoxia. This protocol paper describes the background, design and statistical analysis plan for the trial.
Identifiants
pubmed: 34310694
doi: 10.1111/aas.13956
pmc: PMC8441913
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1497-1504Subventions
Organisme : Danish Ministry of Higher Education and Research
ID : 0238-00004B
Informations de copyright
© 2021 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Crit Care Med. 2021 Mar 1;49(3):e219-e234
pubmed: 33555780
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
N Engl J Med. 2012 Aug 30;367(9):787-90
pubmed: 22830434
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
BMC Med Res Methodol. 2014 Mar 04;14:34
pubmed: 24588900
Lancet Respir Med. 2020 Dec;8(12):1209-1218
pubmed: 32861275
BMC Med Res Methodol. 2014 Nov 21;14:120
pubmed: 25416419
JAMA. 2019 Jan 15;321(2):145-146
pubmed: 30556836
J Crit Care. 2013 Oct;28(5):647-54
pubmed: 23683560
Z Evid Fortbild Qual Gesundhwes. 2012;106(7):496-9
pubmed: 22981026
Intensive Care Med. 2011 Dec;37(12):1932-41
pubmed: 21997128
Anaesth Intensive Care. 2013 Jul;41(4):505-14
pubmed: 23808511
Acta Anaesthesiol Scand. 2020 Jul;64(6):847-856
pubmed: 32068884
J Clin Epidemiol. 2010 Aug;63(8):e1-37
pubmed: 20346624
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Acta Anaesthesiol Scand. 2021 Nov;65(10):1497-1504
pubmed: 34310694
Crit Care. 2015 Aug 17;19:284
pubmed: 26278383
N Engl J Med. 2021 Apr 8;384(14):1301-1311
pubmed: 33471452
Lancet. 2018 Apr 28;391(10131):1693-1705
pubmed: 29726345
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Acta Anaesthesiol Scand. 2019 Aug;63(7):956-965
pubmed: 30883686
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
Fed Regist. 1998 Sep 16;63(179):49583-98
pubmed: 10185190
Chest. 2021 Jan;159(1):154-173
pubmed: 32687907
Am J Respir Cell Mol Biol. 2003 Oct;29(4):427-31
pubmed: 14500253
J Appl Physiol (1985). 2003 Dec;95(6):2453-61
pubmed: 12937024
Lancet. 2018 Dec 8;392(10163):2436-2437
pubmed: 30527413
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Anaesthesia. 2020 Oct;75(10):1340-1349
pubmed: 32602561
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Acta Anaesthesiol Scand. 2021 Jan;65(1):68-75
pubmed: 32929715
Lancet. 1995 Jun 3;345(8962):1387-91
pubmed: 7760608